Avanos Medical, Inc. (AVNS): Modelo de negócios Canvas [Jan-2025 Atualizado]

No cenário dinâmico da tecnologia médica, a Avanos Medical, Inc. (AVNS) surge como uma força transformadora, navegando estrategicamente no complexo ecossistema de saúde por meio de seu modelo de negócios meticulosamente criado. Ao integrar perfeitamente soluções inovadoras de gerenciamento da dor, intervenções cirúrgicas avançadas e tecnologias de dispositivos médicos de ponta, o Avanos se posicionou como um participante fundamental no fornecimento de inovações em saúde centradas no paciente. Essa tela abrangente do modelo de negócios revela a complexa estrutura estratégica que impulsiona o notável sucesso da AVNS, oferecendo um vislumbre sem precedentes sobre como a empresa cria sistematicamente, oferece e captura valor na indústria de dispositivos médicos altamente competitivos.

Avanos Medical, Inc. (AVNS) - Modelo de negócios: Parcerias -chave

Fabricantes de dispositivos médicos estratégicos

A Avanos Medical colabora com os seguintes fabricantes estratégicos de dispositivos médicos:

Parceiro	Foco em parceria	Ano estabelecido
Cardinal Health	Cadeia de suprimentos e distribuição	2018
Medline Industries	Aquisição de dispositivos médicos	2019

Distribuidores e fornecedores de assistência médica

As principais parcerias de distribuição de saúde incluem:

• Amerisourcebergen
• McKesson Corporation
• Henry Schein Medical

Instituições de pesquisa e universidades

Parceiros de colaboração de pesquisa da Avanos Medical:

Instituição	Área de pesquisa	Valor de colaboração
Universidade Johns Hopkins	Tecnologias de gerenciamento da dor	US $ 2,3 milhões anualmente
Escola de Medicina de Stanford	Inovação cirúrgica	US $ 1,7 milhão anualmente

Centros cirúrgicos e hospitais

Parcerias de rede do Hospital da Avanos Medical:

• Clínica Mayo
• Clínica de Cleveland
• NYU LANGONE SAÚDE

Parceiros de Inovação em Tecnologia Médica

Detalhes da colaboração de inovação tecnológica:

Parceiro	Foco na inovação	Investimento
Medtronic	Soluções avançadas de gerenciamento da dor	US $ 5,6 milhões em investimento em P&D
Boston Scientific	Tecnologias intervencionistas	Pesquisa colaborativa de US $ 4,2 milhões

Avanos Medical, Inc. (AVNS) - Modelo de negócios: Atividades -chave

Pesquisa e desenvolvimento de dispositivos médicos

Investimento de P&D em 2023: US $ 74,2 milhões

Áreas de foco em P&D	Porcentagem de investimento
Tecnologias de gerenciamento da dor	42%
Produtos intervencionistas cirúrgicos	33%
Soluções respiratórias avançadas	25%

Projeto de solução de gerenciamento de dor avançada

Portfólio total de produtos para gerenciamento da dor: 17 dispositivos médicos especializados

• Sistemas de intervenção da dor crônica
• Tecnologias de gerenciamento da dor aguda
• Bloqueio nervoso e soluções de anestesia regional

Fabricação de produtos cirúrgicos e intervencionistas

Capacidade anual de fabricação: 2,4 milhões de dispositivos médicos

Locais de fabricação	Volume de produção
Estados Unidos	1,6 milhão de unidades
México	0,8 milhão de unidades

Controle de qualidade e conformidade regulatória

Certificações regulatórias: FDA, ISO 13485: 2016

• Frequência anual de auditoria de qualidade: 4 vezes por ano
• Investimento de conformidade: US $ 22,3 milhões em 2023
• Pessoal de controle de qualidade: 126 especialistas

Marketing de produtos médicos e vendas

2023 Orçamento de marketing: US $ 98,6 milhões

Canal de vendas	Contribuição da receita
Vendas diretas	62%
Rede de distribuidores	38%

Avanos Medical, Inc. (AVNS) - Modelo de negócios: Recursos -chave

Experiência especializada em engenharia médica

A partir de 2024, a Avanos Medical emprega aproximadamente 2.200 profissionais com formação especializada em engenharia médica. A equipe de engenharia da empresa possui 272 patentes ativas em tecnologias de dispositivos médicos.

Instalações de fabricação avançadas

Localização	Tamanho da instalação	Capacidade de produção
Austin, Texas	85.000 pés quadrados	3,2 milhões de dispositivos médicos anualmente
Alpharetta, Geórgia	65.000 pés quadrados	2,7 milhões de dispositivos médicos anualmente

Propriedade intelectual e patentes de dispositivos médicos

O portfólio atual de patentes inclui:

• 272 patentes de dispositivos médicos ativos
• 87 pedidos de patente pendente
• Avaliação de patentes estimada em US $ 124 milhões

Equipe de pesquisa e desenvolvimento

Investimento de P&D em 2023: US $ 87,3 milhões, representando 6,4% da receita total da empresa.

Infraestrutura de tecnologia médica

Investimentos de infraestrutura de tecnologia:

• Infraestrutura de computação em nuvem: US $ 12,4 milhões
• Sistemas de imagem médica avançada: US $ 9,7 milhões
• Plataformas de pesquisa de IA e aprendizado de máquina: US $ 6,2 milhões

Avanos Medical, Inc. (AVNS) - Modelo de negócios: proposições de valor

Soluções inovadoras de dispositivos médicos

A Avanos Medical, Inc. relatou receita total de US $ 812,4 milhões para o ano fiscal de 2022. As soluções inovadoras de dispositivos médicos da empresa se concentram em linhas de produtos especializadas em vários segmentos de saúde.

Categoria de produto	Contribuição da receita	Segmento de mercado
Dispositivos cirúrgicos	US $ 342,6 milhões	Soluções da sala de operações
Tecnologias de gerenciamento da dor	US $ 270,8 milhões	Gerenciamento da dor intervencionista
Produtos de cuidados respiratórios	US $ 199 milhões	Hospital e Cuidado em casa

Tecnologias avançadas de gerenciamento da dor

A Avanos Medical é especializada em tecnologias de gerenciamento da dor, com foco em soluções intervencionistas.

• CRIONIEN* Tratamento de radiofrequência resfriada: penetração de mercado de 17% no segmento de gerenciamento de dor crônico
• Sistemas avançados de cateter de bloqueio nervoso com 92% de classificação de eficácia clínica
• Portfólio de gerenciamento de dor proprietário gerando US $ 270,8 milhões em receita anual

Produtos de intervenção cirúrgica de alta qualidade

A linha de produtos de intervenção cirúrgica gera receita significativa com tecnologias médicas precisas.

Linha de produtos cirúrgicos	Quota de mercado	Receita anual
Dispositivos de fechamento de feridas cirúrgicas	12.5%	US $ 156,3 milhões
Sistemas de drenagem cirúrgica	8.7%	US $ 112,4 milhões

Inovações em saúde centradas no paciente

A Avanos Medical investiu US $ 64,2 milhões em pesquisa e desenvolvimento durante 2022, com foco em soluções médicas centradas no paciente.

• 3 novas patentes arquivadas em tecnologias de monitoramento de pacientes
• Taxa de sucesso do ensaio clínico de 76% para novos dispositivos médicos
• Classificação de satisfação do paciente de 94% nas linhas de produtos

Projeto de equipamento médico de precisão

Abordagem de projeto de precisão suportada por investimentos substanciais de pesquisa.

Investimento de design	Tamanho da equipe de engenharia	Ciclo de desenvolvimento de produtos
US $ 64,2 milhões em P&D Orçamento	387 Profissionais de engenharia	18-24 meses por produto

Avanos Medical, Inc. (AVNS) - Modelo de Negócios: Relacionamentos do Cliente

Equipes de suporte de vendas diretas

O Avanos Medical mantém 127 representantes de vendas diretas a partir do quarto trimestre de 2023, cobrindo instalações de saúde nos Estados Unidos. Compensação média anual de representação de vendas: US $ 185.700.

Métrica da equipe de vendas	2023 dados
Total de representantes de vendas	127
Compensação média anual	$185,700
Cobertura geográfica	Estados Unidos

Consulta técnica de produto médico

TEQUICAL DE CONSULTA TEMPERAÇÃO TAMANHO: 42 especialistas em produtos médicos especializados. Tempo médio de resposta para consultas técnicas: 2,4 horas.

• Disponibilidade de suporte técnico 24/7
• Serviços de consulta multilíngue
• Duração média de consulta de especialistas: 47 minutos

Plataformas de atendimento ao cliente online

Os canais de atendimento ao cliente digital incluem:

• Portal da Web com 99,7% de tempo de atividade
• Downloads de aplicativos móveis: 42.500 em 2023
• Tempo médio de resolução de interação digital: 3,2 horas

Programas de treinamento profissional médico

Programa de Treinamento Métrica	2023 dados
Total de sessões de treinamento	218
Participantes treinados	3,642
Duração média do treinamento	6,5 horas

Suporte personalizado de dispositivo médico

Métricas de suporte personalizado:

• Gerentes de conta dedicados: 87
• Classificação de satisfação do cliente: 94,3%
• Tempo médio de personalização do dispositivo: 5,6 dias

Avanos Medical, Inc. (AVNS) - Modelo de negócios: canais

Força de vendas direta

A partir de 2024, a Avanos Medical mantém uma equipe de vendas interna dedicada de aproximadamente 287 representantes de vendas diretas focadas nos mercados cirúrgicos e intervencionistas.

Categoria de canal de vendas	Número de representantes	Segmento de mercado -alvo
Equipe de vendas cirúrgicas	162	Hospitais e centros cirúrgicos
Equipe de vendas intervencionistas	125	Clínicas médicas especializadas

Redes de distribuidores de dispositivos médicos

Avanos Medical Partners com 73 distribuidores nacionais e internacionais de dispositivos médicos em 12 países.

• Rede de distribuição norte -americana: 42 distribuidores
• Rede Europeia de Distribuição: 19 distribuidores
• Rede de distribuição da Ásia-Pacífico: 12 distribuidores

Plataformas online de comércio eletrônico

Os canais de vendas digitais geram US $ 47,3 milhões em receita anual da Avanos Medical em 2024.

Plataforma de comércio eletrônico	Volume anual de vendas	Porcentagem de receita digital
Site da empresa direta	US $ 22,6 milhões	47.8%
Mercados médicos de terceiros	US $ 24,7 milhões	52.2%

Exposições da Conferência Médica

A Avanos Medical participa de 37 conferências médicas anualmente, com um investimento estimado em exibição de US $ 2,1 milhões.

Marketing digital profissional de saúde

Orçamento de marketing digital alocado: US $ 6,5 milhões em 2024, visando profissionais de saúde em vários canais digitais.

Canal de marketing digital	Orçamento alocado	Público -alvo
Publicidade profissional do LinkedIn	US $ 2,3 milhões	Médicos e administradores de saúde
Plataformas médicas especializadas da Web	US $ 1,8 milhão	Especialistas médicos
Publicidade digital programática	US $ 2,4 milhões	Broad Healthcare Professional segmento

Avanos Medical, Inc. (AVNS) - Modelo de negócios: segmentos de clientes

Hospitais e centros cirúrgicos

A partir de 2023, o Avanos Medical atende a aproximadamente 5.600 hospitais nos Estados Unidos. A penetração do mercado da empresa inclui:

Tipo de hospital	Número de instalações	Penetração de mercado
Grandes centros médicos acadêmicos	287	82%
Hospitais comunitários	4,813	65%
Hospitais cirúrgicos especializados	500	73%

Anestesiologistas e especialistas em gerenciamento da dor

Avanos Medical metas aproximadamente 52.000 anestesiologistas praticantes nos Estados Unidos.

• Valor do segmento de mercado de gerenciamento da dor: US $ 71,3 bilhões em 2023
• Base de clientes especializados direcionados: 18.500 profissionais de gerenciamento da dor
• Poder anual de compra de produto por especialista: US $ 157.000

Médicos intervencionistas

Redução do segmento de clientes para especialistas em intervenção:

Especialidade	Número de praticantes	Gastos médios anuais do produto
Radiologistas intervencionistas	6,200	$94,500
Cardiologistas intervencionistas	8,700	$112,300

Departamentos de Compras de Saúde

O segmento de clientes de compras da Avanos Medical inclui:

• Organizações de compras em grupo (GPOs): 8 principais redes nacionais
• Total de departamentos de aquisição servidos: 3.200
• Valor anual do contrato: US $ 42,6 milhões

Centros cirúrgicos ambulatoriais

Detalhes do segmento de mercado para centros cirúrgicos ambulatoriais:

Tipo central	Total de centros	Penetração do mercado de Avanos	Contribuição anual da receita
ASCs ortopédicos	4,100	57%	US $ 23,4 milhões
ASCs multi-especializado	5,600	49%	US $ 18,7 milhões

Avanos Medical, Inc. (AVNS) - Modelo de negócios: estrutura de custos

Investimentos de pesquisa e desenvolvimento

Para o ano fiscal de 2022, a Avanos Medical, Inc. investiu US $ 40,5 milhões em despesas de pesquisa e desenvolvimento, representando 6,1% da receita total.

Ano	Investimento em P&D	Porcentagem de receita
2022	US $ 40,5 milhões	6.1%
2021	US $ 38,2 milhões	5.8%

Despesas de fabricação e produção

Os custos totais de fabricação da Avanos Medical em 2022 foram de aproximadamente US $ 261,7 milhões, o que inclui mão de obra direta, materiais e despesas gerais.

• Custos de material direto: US $ 142,3 milhões
• Custos de mão -de -obra direta: US $ 63,5 milhões
• Mercancada de fabricação: US $ 55,9 milhões

Despesas de vendas e marketing

As despesas de vendas e marketing da Avanos Medical em 2022 totalizaram US $ 146,3 milhões, representando 22% da receita total.

Categoria de despesa	Quantia
Custos de pessoal de vendas	US $ 82,7 milhões
Campanhas de marketing	US $ 38,5 milhões
Infraestrutura de suporte de vendas	US $ 25,1 milhões

Custos de conformidade regulatória

As despesas de conformidade regulatória da Avanos Medical em 2022 foram de US $ 23,6 milhões, o que inclui as atividades de garantia de qualidade, certificação e conformidade legal.

Manutenção de infraestrutura de tecnologia

Os custos de manutenção de tecnologia e infraestrutura de TI para 2022 totalizaram US $ 32,4 milhões, cobrindo software, hardware, segurança cibernética e investimentos em infraestrutura digital.

Categoria de custo de tecnologia	Quantia
Licenciamento de software	US $ 12,6 milhões
Infraestrutura de hardware	US $ 9,8 milhões
Investimentos de segurança cibernética	US $ 6,5 milhões
Iniciativas de transformação digital	US $ 3,5 milhões

Avanos Medical, Inc. (AVNS) - Modelo de negócios: fluxos de receita

Vendas de produtos para dispositivos médicos

Ano fiscal de 2022 Receita total: US $ 806,4 milhões

Categoria de produto	Receita ($ m)	Percentagem
Gerenciamento da dor crônica	$380.2	47.1%
Gerenciamento da dor intervencionista	$276.5	34.3%
Produtos cirúrgicos	$149.7	18.6%

Receitas de equipamentos de intervenção cirúrgica

2022 Receita de equipamento cirúrgico: US $ 149,7 milhões

• Produtos de drenagem cirúrgica especializados
• Soluções de gerenciamento de feridas cirúrgicas
• Tecnologias avançadas de intervenção cirúrgica

Licensagem da solução de gerenciamento da dor

Receita de licenciamento para 2022: US $ 42,3 milhões

Categoria de licenciamento	Receita ($ m)
Tecnologia de dor crônica	$28.6
Soluções de dor intervencionistas	$13.7

Contratos de Serviço de Tecnologia Médica

Receita do contrato de serviço para 2022: US $ 33,5 milhões

• Manutenção de dispositivos médicos
• Acordos de suporte técnico
• Serviços de instalação e treinamento

Taxas de manutenção de produtos recorrentes

Receita de taxa de manutenção para 2022: US $ 22,9 milhões

Tipo de manutenção	Receita ($ m)
Dispositivos de dor crônica	$14.6
Manutenção de equipamentos cirúrgicos	$8.3

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Value Propositions

You're looking at the core reasons why customers choose Avanos Medical, Inc. (AVNS) products, grounded in their late 2025 performance data. The value propositions center on clinical differentiation and strategic portfolio focus.

Opioid-sparing, non-invasive chronic pain relief (RFA)

Avanos Medical, Inc. offers Radiofrequency Ablation (RFA) solutions as a key component in addressing the need for alternatives to systemic opioids for pain management. The momentum in this area is clear from recent results.

• Net sales of RFA products grew by 10.5% in the third quarter of 2025.
• The overall Pain Management & Recovery (PM&R) segment net sales for Q3 2025 were $59.0 million, an increase of $1.2 million versus the prior year period.
• This growth reflects sustained momentum in RFA generator sales, which directly resulted in higher procedural volumes across their product lines.

Life-sustaining enteral feeding and neonatal solutions

The Specialty Nutrition Systems (SNS) segment provides vital support for patients requiring long-term nutrition, including neonates. This segment is a primary growth engine for Avanos Medical, Inc.

• SNS achieved 14.5% organic growth in the third quarter of 2025.
• For the first nine months of 2025, SNS net sales reached $317.8 million, representing an increase of $27.3 million compared to the prior year period, driven by 9.1% volume growth.
• The NeoMed product offering, part of the neonatal solutions, exceeded $100 million of annualized revenue as of December 2024, maintaining the number one share position in the US.
• Operating income for the SNS segment for the first nine months of 2025 was $62.1 million, which is 19.5% of SNS net sales.

Safer, more consistent nutrition/medication delivery

Avanos Medical, Inc. focuses on improving the reliability and safety of feeding delivery, particularly through standardization and technology adoption.

The value here is tied to preventing adverse events and ensuring proper nutrient uptake, supported by specific product adoption metrics.

• Short-term feeding portfolio growth is driven by the continued expansion of their US CORTRAK standard of care offerings.
• The shift to new alternatives like the ENFit connectors helps prevent hospital-never events, a critical safety metric in feeding.
• Reimbursement for long-term feeding patients in the US is described as robust and not expected to change soon.

Clinically superior, evidence-based medical devices

The company emphasizes that its devices offer superior clinical outcomes, which drives adoption, especially in the enteral feeding space where CORTRAK is mentioned as a standard of care offering.

Here's a quick look at the segment performance that underpins the overall financial health, which supports continued R&D and market presence:

Metric (As of 9M 2025)	Value	Segment
Total Net Sales	$520.3 million	Company-wide
Total Net Sales Growth (vs prior year)	2.4%	Company-wide
Adjusted Gross Margin (Q3 2025)	52.8%	Company-wide
RFA Product Net Sales Growth (Q3 2025)	10.5%	PM&R
SNS Segment Operating Profit Margin (9M 2025)	19.5%	SNS

Focus on high-growth, core segments for investors

Avanos Medical, Inc. is actively refining its portfolio to concentrate capital and resources on areas with the highest growth potential, signaling a clear strategic direction for investors.

This focus is evidenced by recent portfolio management actions:

• The company announced the divestiture of its Hyaluronic Acid (HA) business on July 31, 2025.
• They are executing an exit from the IV infusion products category, planned for early 2026.
• The acquisition of Nexus Medical is expected to be immediately accretive and provides access to a $70 million market segment.
• Management has initiated a $15 million-$20 million cost savings initiative.
• The full-year 2025 revenue estimate was raised to a range of $690 million to $700 million, with the adjusted EPS estimate raised to $0.85 to $0.95 per share.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Relationships

You're looking at how Avanos Medical, Inc. (AVNS) builds and maintains its ties with the people and institutions that buy its products. This isn't just about transactions; it's about deep integration, especially in specialized areas like pain management and nutrition.

Dedicated clinical training and support for RFA procedures

Avanos Medical, Inc. supports its Radiofrequency Ablation (RFA) solutions with a history of clinical engagement. The company notes having over 20 years of experience working with leading institutions to develop successful pain management programs. The focus here is on ensuring providers can use the technology effectively, which is critical for procedures where patient outcomes are paramount. For instance, the momentum in RFA generator sales, which drove RFA product net sales growth of 10.9% for the nine months ended September 30, 2025, relies on this support structure.

The relationship is reinforced through educational efforts, such as hosting industry symposiums like the one at ASRA 2025, focusing on opioid-sparing therapies.

Long-term contracts with major hospital systems/IDNs

While specific contract values aren't public, the relationship strategy involves deep integration within hospital systems. The growth in the Pain Management & Recovery (PM&R) segment, which saw net sales of $176.2 million for the nine months ended September 30, 2025, reflects ongoing engagement with these facilities. The company's portfolio, including RFA products, is positioned to support hospital operations by offering evidence-based, non-narcotic solutions for chronic pain management, which is a key concern for hospital administrators focused on efficiency and reputation.

Direct-to-patient support for chronic care products

For its Specialty Nutrition Systems (SNS) segment, which provides a lifeline for nutrition from hospital to home, Avanos Medical, Inc. is taking steps to enhance direct control over the customer experience. A concrete action in this area is the expansion of direct operations for MIC-KEY enteral feeding products into the United Kingdom, effective July 2025. This move signals a commitment to a more direct relationship with the end-user base for chronic care. The SNS segment showed strong performance, with net sales of $317.8 million and 9.1% volume growth for the first nine months of 2025.

High-touch, consultative sales for capital equipment

The sales approach for capital equipment, like RFA generators, is consultative, focusing on providing a full suite of options-cooled, 3-tined, and conventional RFA-to tailor treatment plans. This consultative model supports the sales momentum seen in the PM&R segment. The company has a dedicated sales force and customer support team with significant industry experience and product training supporting its franchises.

Digital tools for product reordering and education

Avanos Medical, Inc. is focused on operational optimization, which includes digital components, though specific usage metrics for reordering aren't detailed. The company's overall transformation priorities through 2025 included strategic and commercial optimization. The company employs more than 2,200 people worldwide, supporting its global footprint and product marketing efforts. The overall net sales for the last twelve months ending September 30, 2025, reached $699.90 million.

Here's a quick look at the scale of the business supporting these relationships as of late 2025:

Metric	Value (Latest Reported Period)
Total Net Sales (Last Twelve Months ending Q3 2025)	$699.90 million
SNS Segment Net Sales (9 Months ended Sep 30, 2025)	$317.8 million
PM&R Segment Net Sales (9 Months ended Sep 30, 2025)	$176.2 million
RFA Product Net Sales Growth (9 Months ended Sep 30, 2025)	10.9%
Total Employees Worldwide (As of 2024)	More than 2,200

The company's 2025 estimated revenue guidance was set between $665 million and $685 million.

The relationship strategy is supported by a structure that includes:

• A dedicated sales force for each franchise.
• Customer support teams with significant industry experience.
• A medical education program with HCP-led training.
• Local, in-person support and training availability.

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Channels

You're looking at how Avanos Medical, Inc. gets its clinically superior medical device solutions into the hands of healthcare providers and patients as of late 2025. The channel strategy is clearly evolving, moving toward more direct control where it makes strategic sense, while still relying on established networks for broad reach.

Here's a quick look at the top-line financial context for the channels to consider:

Metric	Value (as of late 2025)	Period/Date
Trailing 12-Month Revenue	$700 Million USD	As of September 30, 2025
Full-Year 2025 Net Sales Guidance (Raised)	$690 Million to $700 Million	Updated Guidance
Q3 2025 Enteral Feeding Unit Revenue	$82.7 Million	Q3 2025
Q3 2025 Neonate Solutions Unit Revenue	$31.3 Million	Q3 2025

The company develops, manufactures, and markets its recognized brands globally, holding leading market positions in multiple product categories across its portfolio.

Direct sales force to hospitals and ASCs

Avanos Medical, Inc. markets its products generally directly to hospitals and other healthcare providers. This direct engagement is crucial for complex devices and capital equipment sales, especially within the Pain Management & Recovery (PM&R) segment, which includes Radiofrequency Ablation (RFA) generator sales that grew 10.5% year over year in Q3 2025 to $34.6 million. The direct sales effort supports the company's commitment to reducing opioid use and helping patients move from surgery to recovery.

Third-party medical device distributors globally

While pushing for direct relationships, a significant portion of sales still flows through third-party wholesale distributors. For the year ended December 31, 2024, approximately 50% of North America net sales were executed via these distributors. Two major distributors, McKesson Corporation and Medline Industries, accounted for approximately 18% and 17% of consolidated net sales in 2024, respectively. Globally, the MIC-KEY product line, which is part of the Specialty Nutrition Systems (SNS) segment, is sold in over 60 countries across six continents.

Direct-to-home patient supply for chronic care

A key part of the Avanos Medical mission involves providing a vital lifeline for nutrition to patients from hospital to home. This is primarily served through the Chronic Care franchise, now integrated into the Digestive Health focus within the combined commercial organization. The Enteral feeding unit, which supports this continuum of care, generated net sales of $82.7 million in the third quarter of 2025, representing a 14.9% increase year over year.

Strategic transition to direct operations (e.g., UK MIC-KEY)

Avanos Medical, Inc. is actively strengthening its direct control over key product lines. A major example is the strategic transition for the MIC-KEY enteral feeding products in the United Kingdom. Effective July 25, 2025, Avanos took direct responsibility for sales and distribution, ending a 29-year distribution partnership with Vygon UK. This move is intended to enhance customer relationships and improve service efficiency by eliminating the intermediary.

E-commerce and online portals for consumables

The company is focused on go-to-market strategies to accelerate growth, which includes enhancing customer engagement. The channels used for consumables, which are typically lower-touch items supporting the core devices, are increasingly being managed through digital means. The company plans to guide healthcare facilities through new ordering processes following the UK transition to ensure continuity.

• The company is focused on advancing its strategic segments in PM&R and SNS following the July 2025 divestiture of its Hyaluronic Acid (HA) product line.
• The SNS segment saw volume growth of 14% in Q3 2025, driven by long-term feeding products.
• The company's overall strategy involves commercial optimization and supply chain effectiveness.
• The direct control in the UK aims to ensure uninterrupted access to MIC-KEY products.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Customer Segments

Hospitals and Integrated Delivery Networks (IDNs)

• SNS segment net sales for the third quarter of 2025 totaled $114.0 million.
• PM&R segment net sales for the third quarter of 2025 totaled $59 million.
• The Specialty Nutrition Systems (SNS) segment recorded volume growth of 14.0% in the third quarter of 2025.
• The full-year 2025 revenue guidance is between $690 million and $700 million.

Pain management specialists and anesthesiologists

Pain Management Sub-Segment	Q3 2025 Net Sales (in millions)	Year-over-Year Change
Radiofrequency Ablation (RFA) products	$34.60 million	Up 10.5%
Surgical pain and recovery	$24.40 million	Down 7.9%

Neonatal and Pediatric Intensive Care Units (NICUs/PICUs)

• Neonate solutions unit revenue for the third quarter of 2025 amounted to $31.3 million.
• Neonate solutions revenue growth year-over-year for the third quarter of 2025 was 19.5%.
• Avanos Medical, Inc. completed the acquisition of Nexus Medical, which is expected to deliver immediate value in NICU and PICU care.

Patients requiring long-term enteral feeding

• Enteral feeding unit revenue for the third quarter of 2025 totaled $82.70 million.
• Enteral feeding revenue growth year-over-year for the third quarter of 2025 was 14.9%.
• The company noted strong demand for its long-term feeding products in the third quarter of 2025.

Ambulatory Surgery Centers (ASCs) for RFA procedures

• RFA product net sales grew 10.5% year-over-year in the third quarter of 2025.
• RFA capital equipment sales drove procedural volumes in the third quarter of 2025.
• The Radiofrequency Ablation (RFA) business posted double-digit growth in the third quarter of 2025 compared to the previous year.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Avanos Medical, Inc. (AVNS) engine as of late 2025. It's a mix of necessary investment for growth, the lingering effects of external pressures, and costs tied to strategic restructuring. Honestly, keeping the lights on and investing for the future requires significant outlay across the board.

High Cost of Goods Sold (COGS) due to tariff headwinds

Tariffs are definitely biting into the gross margin. For the second quarter of 2025, the reported gross profit margin was 52.6%, a notable drop from 55.7% in the prior year period. Management specifically cited higher tariffs as a primary driver for this contraction, alongside lower pricing on the Hyaluronic Acid (HA) products before that line was divested. Looking ahead, the full-year 2025 free cash flow forecast is explicitly inclusive of an estimated $18 million tariff impact. The company is actively working on mitigation, including supply-chain relocation and a plan to exit China for neonatal syringe production by mid-2026, which is driving higher capital expenditures in 2025.

Significant R&D and SG&A investment for core growth

Investing in the core segments-Specialty Nutrition Systems (SNS) and Pain Management & Recovery (PM&R)-means keeping R&D and SG&A spending at meaningful levels. You see the discipline in the latest quarterly figures, but the absolute spend is still substantial. Here's a snapshot of the most recent reported operating expenses from the third quarter of 2025:

Expense Category	Q3 2025 Amount	Year-over-Year Change	Context/Metric
Selling and General Expenses	$83.5 million	Increased 3.2%	Reported for the quarter
Research and Development Expenses	$5.8 million	Decreased 7.9%	Reported for the quarter
Adjusted SG&A as % of Revenue	40.6%	N/A	Q3 2025 metric
SG&A as % of Net Sales (Full Year 2024)	46.3%	Decreased from 49.8%	Driven by transformation and divestiture costs

The company is streamlining management and revamping R&D with a hybrid model to accelerate product development, aiming for $15 million to $20 million in run-rate annualized cost savings by 2026.

Transformation costs, including $10 million one-time Q4 2025 charges

The ongoing transformation process, initiated in January 2023, carries specific one-time costs. Management anticipates approximately $10 million in one-time cash charges related to expanded cost programs, with the majority expected to be incurred in 2025. This $10 million in transformation-related charges is explicitly factored into the full-year 2025 free cash flow forecast of $25 million-$30 million.

Manufacturing and supply chain expenses

While specific manufacturing cost line items aren't broken out separately from COGS, supply chain expenses are embedded within the margin pressures and capital expenditure plans. The company is focused on improving profitability in certain areas, such as transitioning the Game Ready U.S. Rental segment to a distribution arrangement with WRS Group. Furthermore, capital expenditures are higher in 2025 to support the planned exit from China for neonatal syringe production by mid-2026.

Amortization of acquired intangibles (e.g., Nexus Medical)

Amortization of intangible assets, stemming from prior business acquisitions, is a consistent non-cash cost. The most recent reported figure for this expense in the second quarter of 2025 was $3.0 million on an adjusted, non-GAAP basis. For comparison, the full-year 2024 amortization was $25.2 million. The recent acquisition of Nexus Medical is expected to be immediately accretive to revenue and earnings per share, meaning its related amortization will be a new component of the cost structure moving forward.

You should track the quarterly non-GAAP intangibles amortization:

• Q2 2025: $3.0 million
• Q1 2025: $2.9 million
• Full Year 2024: $25.2 million

Finance: draft 13-week cash view by Friday.

Avanos Medical, Inc. (AVNS) - Canvas Business Model: Revenue Streams

You're looking at the core ways Avanos Medical, Inc. brings in money as of late 2025, which is heavily influenced by their recent strategic moves and acquisitions.

The company has officially raised and narrowed its full-year 2025 revenue guidance following the third quarter results.

Revenue Component	Latest Reported Period Data (Q3 2025)	FY 2025 Guidance/Estimate
Total Net Sales (FY 2025 Estimate)	$177.8 million (Q3 Actual)	$690 million to $700 million
Specialty Nutrition Systems (SNS) Net Sales	$114 million	Part of Total Guidance
Pain Management & Recovery (PM&R) Net Sales	$59 million	Part of Total Guidance
Radiofrequency Ablation (RFA) Product Sales	$34.6 million (Q3 Actual)	Q2 2025 Growth: 13.7%
Nexus Medical Acquisition Accretion	N/A (Acquisition closed 9/15)	Roughly $5 million in 2025

Sales of Specialty Nutrition Systems (SNS) products remain a primary driver, showing strong momentum.

• SNS segment recorded net sales of $114 million in the third quarter of 2025.
• This reflected 14% volume growth in the third quarter.
• The segment saw double-digit growth, anchored by enteral feeding and neonate solutions.

Revenue from Pain Management & Recovery (PM&R) devices and consumables is also critical, though it includes a mixed performance across its sub-categories.

The Radiofrequency Ablation (RFA) business within PM&R is a key growth area for device sales.

• Net sales of RFA products grew 10.5% year-over-year in Q3 2025, reaching $34.6 million.
• This follows a reported 13.7% growth rate for RFA product sales in the second quarter of 2025.
• The segment's overall growth was partially offset by a year-over-year decline of 7.9% in surgical pain and recovery unit sales.

Furthermore, the recent strategic move to acquire Nexus Medical is expected to contribute directly to the top line.

Revenue accretion from the Nexus Medical acquisition is factored into the full-year estimate, expected to contribute roughly $5 million to the 2025 total revenue figure. Finance: review the Q4 forecast to ensure the $5 million accretion is fully captured within the $690-$700 million range by Friday.